52 Week Study of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Recruiting

Phase 3

XYOSTED®52 Week Study of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Sponsor:

Halozyme Therapeutics

Code:

NCT06689085

Conditions

Hypogonadism, Male

Eligibility Criteria

Sex: Male

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Testosterone enanthate

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-27. This information was provided to ClinicalTrials.gov by Halozyme Therapeutics on 2025-07-14.